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OVER a period of 3 years (May 2. 1990 to April 15. 1993). 43 consecutive patients were given 45 intesti-
nal allografts at the University of Pittsburgh. The basic 
immunosuppressive therapy was FK 506. Twenty-one 
patients were adults and 22 were children. Fifteen received 
an intestine alone. 21 received an intestine in continuity 
with the liver. and 7 received a multivisceral graft that 
contained 4 or more organs (liver in 6). The ascending and 
right transverse colon were included with the small bowel 
in 13 recipients. almost evenly distributed between the 
three groups. The donors were all ABO-identical and 
HLA-histoincompatible. The lymphocytotoxic cross-
match was positive in two cases. No attempts were made 
to alter the graft immunologic tissue with antilymphocyte 
preparations or other modalities. One of the isolated 
intestinal and one of the combined liver-intestinal recipi-
ents required retransplantation after 667 and 47 days. 
respectively. because of chronic and acute rejection. After 
6 to 40 months. 30 of the 43 patients are alive. 29 bearing 
grafts. Of these. 25 (86%) are supported nutritionally solely 
with their functioning grafts. The surgical techniques. 
details of patient and graft survival. as well as quality of 




Intravenous FK 506. steroids. and prostaglandin EI (prostln) were 
begun Intraoperatively as previously descnbed ...... Enteral admin-
i,tratlon of FK 506 was staned I to .2 weeks after transplantation 
with ,eventl days of overlap with intr.lvenous treatment. The 
target range ot FK 506 trough plasma levels was between 3 to I 
nlUmL. During the study penod. the FK 506 doses. plasma trough 
levels. and the prednisone doses were similar in the 3 kinds of 
allograft reCipients. A low dose of azathioprine (I to ~ mg/kg/dl 
was added in 22 patients. 
Augmented immunosuppressive therapy was initiated during 
reJection episodes. based upon their severitv. A sterOid bolus was 
given and FK 506 dosage was increased when this was possible 
Without drug toxicity. A steroid recycle for 5 days and/or a 7·day 
course of OKT3 were backup options. 
MOnitOring of Graft Rejection 
Detectton of grJ.t't rejection was based pnmanly on dinicalobser-
vallon,. endo>coplC (indings. and histopathologic ,tudles of endo· 
,cOpte·guldc:d mucosal biopSies. Graft c:ndoscopy With random 
I11llitlPic mucosal biopsies tpantcularlv of the Iic:uml was accom-
plished at it:ast once per week for the hrst 3 months. monthly for 
(he n.:'(t .1 months. and c:verv 3 (0 h months thereafter and 
\1 hen':\'<!f II II a~ dimcallv tndicated. Thc adopted cntena for the 
dia~!lo~fD ot tnh!~ttnal allogmft relc:ctton are Jc:scnbed dsewhere .. 
RESULTS 
Acute Rejection 
With a mean follow-up of 15 ± 10 months. only 2 patients 
(both with combined liver-intestine grafts) were spared 
clinical or histopathologic diagnosis of intestinal graft 
rejection. Although the clinical diagnosis of rejection was 
made in 95% of cases. this was confirmed histologically in 
only 31 patients (72%). The mean postoperative time to the 
first episode in all cases was 19 ± 28 days; II ± 6 for the 
isolated intestine. 22 ± 34 for the combined liver and 
intestine. and 15 ± 7 for the multivisceral allografts. Most 
of the rejections were mild to moderate. and the number of 
episodes per graft were similar for the 3 kinds of intestinal 
allografts with an average of 4.1. Beyond 3 months after 
transplantation. about 50% of the patients in each trans-
plant group experienced rejection of the intestinal graft. 
This often was associated with attempts to reduce immu-
nosuppression because of cytomegaloviral enteritis. post-
transplant Iymphoprolifer.ltive disease. or other opportu-
nistic infections. Twenty-three (\0 isolated intestine. \0 
combined liver-intestine. and 3 multiviscerall of the 45 
grafts required I or more steroid recycles for treatment of 
moderate rejection episodes. OKT3 was used to treat 8 
severe rejection episodes among isolated intestinal (n = 5), 
combined liver-intestinal (n = I). and multivisceral recip-
ients (n = 2). 
Twelve of the 28 composite visceral grafts (43%) that 
-:ontained liver experienced histologically diagnosed and 
-:linically treated liver allograft rejection. The number of 
I!pisodes per graft was 0.6. On 88 occasions on which both 
liver and small bowel biopsies were taken simultaneously 
or closely together. 47 of the dual specimens (53%) had no 
signs of rejection in either organs. 12 (14%) had rejection in 
both. 15 (17%) had rejection only in the liver. and 14 (16%) 
had rejection in the intestine only. 
Five of the 13 bowel grafts 08%) that included colon 
showed histologic evidence of colonic rl!jl!ction at some 
time. None of the multivisceral grafts had histopathologi-
cally proven gastric rejection. but I developed 2 c:pisodes 
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of pancreatitis that responded to augmented immunosup-
pressive therapy. 
Chronic Rejection 
The histopathologic examination of full-thickness sections 
of 6 resected grafts (5 isolated intestine. I combined 
liver-intestine) showed chronic rejection in 2 of the iso-
lated intestinal grafts. In addition. one combined liver-
intestine recipient with strong positive cross-match devel-
oped chronic rejection of both organs. This patient died of 
hepatorenal failure with the graft in place. 
Rejection and Graft Loss 
Eight of the 16 (6 isolated intestine. 9 liver-intestine. and I 
multivisceral) implanted grafts that were lost either by 
patient's death (n = 10) or graft removal (n = 6) showed 
histologic evidence of either acute rejection (n = 5). 
chronic rejection (n = 2). or both (n = I). Five were 
isolated intestine (4 recipients) and 3 were combined 
liver-intestine (2 recipients). Graft enterectomy (n = 5) 
rescued only one of the 4 isolated intestinal recipients. and 
the 2 combined liver-intestinal recipients died despite 
successful graft replacement in I. Refractory rejection of 
the isolated intestinal grafts was precipitated by a signifi-
cant reduction in immunosuppression in 4 and misdiagno-
sis of rejection in I. The reduction or withdrawal of 
immunosuppression was due to either drug noncompli-
ance, cytomegaloviral enteritis. respiratory syncytial viral 
pneumonia. or demyelination of the brain white matter. 
The three combined liver-intestinal grafts were rejected 
despite augmented immunosuppressive therapy. 
Graft-Versus-Host Disease 
Using standard histologic and in situ hybridization tech-
niques. graft-versus-host disease was unequivocally diag-
nosed in only I combined Iiver-mtestine pediatric recipient 
who had preexisting immunoglobulin (lg)A deficiency. 
1431 
Light immunosuppression was attempted early in the 
postoperative course because of Pneumocystis carinii 
pneumonia and an intestinal anastomotic leak. 
SUMMARY AND CONCLUSION 
The current results of the present series demonstrate that 
intestinal allografts are more vulnerable to rejection and 
continue to be at a significantly higher risk long after 
transplantation compared with isolated liver allograft re-
cipients. Unexpectedly, a combined liver allograft does 
not protect small bowel from rejection. 
The necessarily continuous heavy immunosuppression 
for these unique recipients is potentially self-defeating. 
This is clearly demonstrated by their high susceptibility to 
early and late infectious complications after transplanta-
tion as reported in this issue.H•9 With the minimal graft-
versus-host disease threat in this clinical trial. our revised 
protocol for future intestinal transplantation is to maximize 
the passenger leukocyte traffic with supplementary bone 
marrow from the same intestinal donor in an attempt to 
augment the development of systemic chimerism and the 
gradual induction of donor-specific nonreactivity.lo 
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